M
Masashi Suzuki
Researcher at Niigata University
Publications - 71
Citations - 1657
Masashi Suzuki is an academic researcher from Niigata University. The author has contributed to research in topics: Hemodialysis & Kidney disease. The author has an hindex of 21, co-authored 70 publications receiving 1578 citations. Previous affiliations of Masashi Suzuki include Social Welfare Department & National Institutes of Natural Sciences, Japan.
Papers
More filters
Journal ArticleDOI
Beta 2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis.
Fumitake Gejyo,Shoji Odani,Toshiyuki Yamada,Noriyuki Honma,Hidehiko Saito,Yasushi Suzuki,Yoichi Nakagawa,Hiroyuki Kobayashi,Yuichiro Maruyama,Yoshihei Hirasawa,Masashi Suzuki,Masaaki Arakawa +11 more
TL;DR: It is demonstrated that the amyloids associated with chronic hemodialysis contains as major component a new form of amyloid fibril protein that is homologous to beta 2-microglobulin.
Journal ArticleDOI
2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease
Yoshiharu Tsubakihara,Shinichi Nishi,Takashi Akiba,Hideki Hirakata,Kunitoshi Iseki,Minoru Kubota,Satoru Kuriyama,Yasuhiro Komatsu,Masashi Suzuki,Shigeru Nakai,Motoshi Hattori,Tetsuya Babazono,Makoto Hiramatsu,Hiroyasu Yamamoto,Masami Bessho,Tadao Akizawa +15 more
TL;DR: The Japanese Society for Dialysis Therapy guideline committee, chaired by Dr Y. Tsubakihara, presents the Japanese guidelines, which replace the “2004 JSDT Guidelines for Renal Anemia in Chronic Hemodialysis Patients,” and contain new, additional guidelines for peritoneal dialysis, non‐dialysis (ND), and pediatric chronic kidney disease (CKD) patients.
Journal ArticleDOI
2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
Fumitake Gejyo,Akira Saito,Tadao Akizawa,Takashi Akiba,Tatsuya Sakai,Masashi Suzuki,Shinichi Nishi,Yoshiharu Tsubakihara,Hideki Hirakata,Masami Bessho +9 more
TL;DR: An original Japanese guideline entitled ‘Guidelines for Renal Anemia in Chronic Hemodialysis Patients’ includes the re‐evaluation of the usage of recombinant human erythropoietin (rHuEPO) with the medical and economical arguments regarding the prognosis and the quality of life of Japanese hemodialysis patients.
Journal ArticleDOI
Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study
Kiyoshi Kurokawa,Tadao Akizawa,Masashi Suzuki,Takashi Akiba,Etsuro Ogata,Eduardo Slatopolsky +5 more
TL;DR: It is concluded that OCT is highly effective in suppressing PTH in dialysis patients with secondary hyperparathyroidism, though hypercalcaemia may be a major factor which limits the use of OCT.
Journal ArticleDOI
High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients.
Yoshiharu Tsubakihara,Fumitake Gejyo,Shinichi Nishi,Yasuhiko Iino,Yuzou Watanabe,Masashi Suzuki,Akira Saito,Takashi Akiba,Hideki Hirakata,Tadao Akizawa +9 more
TL;DR: Maintaining higher Hb levels with darbepoetin alfa better preserved renal function in patients with chronic kidney disease not on dialysis.